Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence

After High-Profile Setbacks In The Clinic

Executive Summary

The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."

You may also be interested in...



End Of An Era As Galapagos CEO Van De Stolpe Retires

Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.

What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?

Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel